Related Experiment Video
Updated: May 2, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Future of cancer vaccines
Hauke Winter1, Bernard A Fox, Dominik Rüttinger
1Laboratory of Clinical and Experimental Tumor Immunology, Department of Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University Munich, Munich, Germany.
Abstract:
Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine sipuleucel-T (Provenge™) in 2010. Even though a major milestone for the field of cancer immunotherapy, many obstacles towards successful integration of vaccination strategies into the oncologists' armamentarium remain. This chapter discusses possible future perspectives for cancer vaccines as a treatment modality in oncology with special focus on biomarkers (response prediction and patient selection), requirements for clinical trial design, and combination therapies (standard of care and new molecular entities).
Insights
Future cancer vaccines require biomarkers for patient selection and optimized clinical trials. Combination therapies are key to integrating these active-specific immunotherapies into oncology practice.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Active-specific immunotherapy has advanced with sipuleucel-T (Provenge™) approval in 2010.
- Despite this milestone, challenges remain in adopting cancer vaccines into routine oncologic care.
Purpose of the Study:
- To explore future perspectives for cancer vaccines in oncology.
- To highlight the importance of biomarkers, clinical trial design, and combination therapies.
Main Methods:
- Review of current landscape of cancer vaccines.
- Discussion of future directions in cancer vaccine development and implementation.
Main Results:
- Biomarkers are crucial for predicting response and selecting patients.
- Clinical trial design needs refinement for vaccine evaluation.
- Combination therapies offer synergistic potential with standard treatments and novel agents.
Conclusions:
- Successful integration of cancer vaccines hinges on biomarker-driven patient selection.
- Optimized clinical trials and strategic combination therapies are essential for advancing cancer vaccine efficacy.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Microorganisms in Medicine and Therapeutics
Cancer Prevention
Some...

